LUNG Stock Analysis: Pulmonx | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 106m USD | 12M Return: 27.3% | US7458481014 | Charts, Fundamentals & Technical Analysis

Total Rating 35
Safety 32
Buy Signal 0.64
Medical Devices
Industry Rotation: +8.4
Market Cap: 106M
Avg Turnover: 504K
Risk 3d forecast
Volatility126%
VaR 5th Pctl19.3%
VaR vs Median-6.32%
Reward TTM
Sharpe Ratio0.66
Rel. Str. IBD97.3
Rel. Str. Peer Group95.6 pctl
Character TTM
Beta2.235
Beta Downside2.074
Hurst Exponent0.624
Choppyness59.4%
Drawdowns 3y
Max DD92.01%
CAGR/Max DD-0.38
CAGR/Mean DD-0.55
EPS (Earnings per Share) EPS (Earnings per Share) of LUNG over the last years for every Quarter: "2021-09": -0.28, "2021-12": -0.35, "2022-03": -0.43, "2022-06": -0.4, "2022-09": -0.38, "2022-12": -0.38, "2023-03": -0.42, "2023-06": -0.43, "2023-09": -0.39, "2023-12": -0.36, "2024-03": -0.36, "2024-06": -0.35, "2024-09": -0.36, "2024-12": -0.33, "2025-03": -0.36, "2025-06": -0.38, "2025-09": -0.34, "2025-12": -0.25, "2026-03": -0.33, "2026-06": -0.24, "2026-09": -0.19,
Last SUE: 1.39
Qual. Beats: 1
Revenue Revenue of LUNG over the last years for every Quarter: 2021-09: 13.261, 2021-12: 13.708, 2022-03: 10.785, 2022-06: 13.95, 2022-09: 13.502, 2022-12: 15.425, 2023-03: 14.535, 2023-06: 17.194, 2023-09: 17.668, 2023-12: 19.278, 2024-03: 18.854, 2024-06: 20.783, 2024-09: 20.387, 2024-12: 23.765, 2025-03: 22.538, 2025-06: 23.859, 2025-09: 21.502, 2025-12: 22.598, 2026-03: 20.586, 2026-06: 22.756, 2026-09: null,
Rev. CAGR: 12.50%
Rev. Trend: 90.4%
Last SUE: 0.59
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Fakeout
Extended 1w

Tailwinds

Rs Leader
Idiosyncratic Leader
Confidence
Ep Pivot

Seasonality

Not enough history
Description: LUNG Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Headlines to Watch Out For
Piotroski VR-10 (Strict) 2.5
Net Income: -48.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.26 > 0.02 and ΔFCF/TA -3.53 > 1.0
NWC/Revenue: 77.45% < 20% (prev 107.8%; Δ -30.30% < -1%)
CFO/TA -0.27 > 3% & CFO -30.6m > Net Income -48.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.32 > 1.5 & < 3
Outstanding Shares: last quarter (42.2m) vs 12m ago 4.95% < -2%
Gross Margin: 77.06% > 18% (prev 73.07%; Δ 3.99% > 0.5%)
Asset Turnover: 66.77% > 50% (prev 61.52%; Δ 5.25% > 0%)
Interest Coverage Ratio: -11.61 > 6 (EBIT TTM -43.8m / Interest Expense TTM 3.77m)
Altman Z'' -13.32
A: 0.59 (Total Current Assets 88.1m - Total Current Liabilities 20.4m) / Total Assets 114.7m
B: -4.75 (Retained Earnings -545.3m / Total Assets 114.7m)
C: -0.33 (EBIT TTM -43.8m / Avg Total Assets 131.0m)
D: 0.52 (Book Value of Equity 39.2m / Total Liabilities 75.5m)
Altman-Z'' = -13.32 = D
Beneish M -2.93
DSRI: 0.77 (Receivables 12.2m/16.4m, Revenue 87.4m/90.5m)
GMI: 0.95 (GM 73.07% / 77.06%)
AQI: 1.63 (AQ_t 0.06 / AQ_t-1 0.04)
SGI: 0.97 (Revenue 87.4m / 90.5m)
TATA: -0.15 (NI -48.1m - CFO -30.6m) / TA 114.7m)
Beneish M = -2.93 (Cap -4..+1) = A
What is the price of LUNG shares?

As of October 29, 2026, the stock is trading at USD 2.52 with a total of 7,243,093 shares traded. Over the past week, the price has changed by +37.70%, over one month by +28.57%, over three months by +101.60% and over the past year by +27.27%.

Current recommended Stop Loss: 2.30 (which is 8.7% or 2 ATR below the current price).

Is LUNG a buy, sell or hold?

Pulmonx has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy LUNG.

  • StrongBuy: 3
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the LUNG price?
Analysts Target Price 3.7 46.8%
Pulmonx (LUNG) - Fundamental Data Overview as of 29 October 2026
Market Cap USD = 106.4m (106.4m USD * 1.0 USD.USD)
P/E Forward = 28.3286
P/S = 1.2377
P/B = 2.499
Revenue TTM = 87.4m USD
EBIT TTM = -43.8m USD
EBITDA TTM = -42.8m USD
Long Term Debt = 37.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.38m USD (from shortTermDebt, last quarter)
Debt = 74.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 18.7m
Net Debt = 19.0m USD (calculated: Debt 74.9m - CCE 55.8m)
Enterprise Value = 125.5m USD (106.4m + Debt 74.9m - CCE 55.8m)
Interest Coverage Ratio = -11.61 (Ebit TTM -43.8m / Interest Expense TTM 3.77m)
EV/FCF = -4.17x (Enterprise Value 125.5m / FCF TTM -30.1m)
FCF Yield = -23.96% (FCF TTM -30.1m / Enterprise Value 125.5m)
FCF Margin = -34.39% (FCF TTM -30.1m / Revenue TTM 87.4m)
Net Margin = -55.03% (Net Income TTM -48.1m / Revenue TTM 87.4m)
Gross Margin = 77.06% ((Revenue TTM 87.4m - Cost of Revenue TTM 20.1m) / Revenue TTM)
Gross Margin QoQ = 77.97% (prev 77.94%)
Tobins Q-Ratio = 1.09 (Enterprise Value 125.5m / Total Assets 114.7m)
Interest Expense / Debt = 5.03% (Interest Expense 3.77m / Debt 74.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -34.6m (EBIT -43.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.51 (Total Current Assets 88.1m / Total Current Liabilities 25.1m)
Debt / Equity = 1.91 (Debt 74.9m / totalStockholderEquity, last quarter 39.2m)
 Debt / EBITDA = -0.44 (negative EBITDA) (Net Debt 19.0m / EBITDA -42.8m)
 Debt / FCF = -0.63 (negative FCF - burning cash) (Net Debt 19.0m / FCF TTM -30.1m)
 Total Stockholder Equity = 49.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.74% (Net Income -48.1m / Total Assets 114.7m)
RoE = -96.66% (Net Income TTM -48.1m / Total Stockholder Equity 49.8m)
RoCE = -50.17% (EBIT -43.8m / Capital Employed (Equity 49.8m + L.T.Debt 37.4m))
 RoIC = -37.84% (negative operating profit) (NOPAT -34.6m / Invested Capital 91.3m)
 WACC = 9.36% (E(106.4m)/V(181.3m) * Re(13.14%) + D(74.9m)/V(181.3m) * Rd(5.03%) * (1-Tc(0.21)))
Discount Rate = 13.14% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 98.33 | Cagr: 3.98%
 [DCF] Fair Price = unknown (Cash Flow -30.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.39 | # QB: 1
Revenue Correlation: 90.37 | Revenue CAGR: 12.50% | SUE: 0.59 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.25 | Chg30d=+1.30% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.98 | Chg30d=+6.37% | Revisions=+57% | GrowthEPS=+26.5% | GrowthRev=+0.3%
EPS next Year (2027-12-31): EPS=-0.92 | Chg30d=+2.12% | Revisions=+57% | GrowthEPS=+5.7% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +64% (up=10, down=1)